Michael Mitchell
Cardiovascular Disease · Arlington, TXNPI 1669436655
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $696 and has fallen 97.9% since, to $15 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in TX, where the typical reported total is $3,258.
Across 58 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$155
- Sanofi-aventis U.S. LLC$150
- AstraZeneca$140
- Novartis$133
- Actelion Pharmaceuticals US, Inc.$91
- Amgen$66
- plus $374 from 15 others
What the payments were for
- Food & beverage$1,109100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 1 | $155 |
| Sanofi-aventis U.S. LLC | 9 | $150 |
| AstraZeneca | 9 | $140 |
| Novartis | 9 | $133 |
| Actelion Pharmaceuticals US, Inc. | 4 | $91 |
| Amgen | 4 | $66 |
| Regeneron Healthcare Solutions, Inc. | 2 | $56 |
| Bardy Diagnostics, Inc. | 2 | $55 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Boehringer Ingelheim | 2 | $32 |
| Johnson & Johnson | 2 | $32 |
| Novo Nordisk | 2 | $29 |
| Boston Scientific | 1 | $23 |
| Astellas Pharma US Inc | 1 | $18 |
| Braemar Manufacturing, LLC | 1 | $16 |
| Osprey Medical Inc | 1 | $15 |
| Mannkind Corporation | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Abbott | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $11 |
| Clarus Therapeutics Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,109 in reported general payments places this provider in the 25th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Arlington
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.